Amerigo Scientific has released high-purity, premium-quality induced pluripotent stem cell (iPSC)-derived cells and engineered reporter iPSC-derived cells, providing robust research tools to support disease mechanism exploration, high-throughput drug screening, and innovative cell therapy development across the life science industry. The announcement, made on June 30, 2026, highlights the company's commitment to advancing biomedical research by offering standardized, traceable cell products.
Induced pluripotent stem cells represent a revolutionary advancement in stem cell research. Unlike embryonic stem cells, iPSCs are generated by genetically reprogramming terminally differentiated somatic cells, eliminating the reliance on fertilized eggs and effectively resolving the practical and ethical dilemmas associated with embryonic stem cell application. These versatile cells can be derived from a wide range of adult tissue cells, including adipose stem cells, amniotic cells, dental pulp cells, and skin fibroblasts, and are capable of large-scale differentiation into diverse cell types, laying a solid foundation for diversified biomedical research.
Cells differentiated from iPSCs exhibit high consistency with in vivo cells and primary cells in transcription, cellular structure, and biological functions, while maintaining stable genetic information. Compared with primary tissue-derived cells, iPSC-derived cells are easier to acquire, culture, and maintain. They are also highly amenable to mainstream genome editing technologies such as CRISPR-Cas9 and TALENs, enabling flexible genetic modification for customized research needs. Patient-specific iPSCs and their differentiated derivatives retain disease-related phenotypic characteristics, making them ideal research models for studying both inherited and acquired human diseases. Human iPSCs carrying disease-causing genotypes also show great potential for accelerating the research and industrialization of novel cell therapies.
Amerigo Scientific's product catalog includes more than 10 kinds of iPSC-derived cell products and supporting reagents, covering multiple cell types and functional reagents for neuroscience, vascular research, and disease modeling. The product range features BrainFast Neuronal Maturation Supplement, human iPSC-derived spinal motor neurons, spinal astrocytes, mixed cortical neurons, midbrain dopaminergic neurons, microglia, medium spiny GABAergic neurons, and endothelial cells. All products are offered in standardized specifications with cell sources and pricing, ensuring a reliable and traceable supply for laboratories and research institutions worldwide.
With outstanding performance and diverse product selections, Amerigo Scientific's iPSC-derived cell products are poised to facilitate deeper exploration in disease pathogenesis, accelerate new drug discovery and toxicity assessment, and drive the continuous progress of global cell therapy research. The company remains committed to providing high-standard biological research materials and supporting the development of cutting-edge life science and translational medicine.
For more information about Amerigo Scientific's iPSC-derived cell products, visit the company's website at https://www.amerigoscientific.com.
